



Technology: Etanercept is a recombinant tumor necrosis factor receptor (“TNFR”):F_c fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.

Etanercept Claims Challenged in IPR and Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

Etanercept Timeline



| | <i>Sandoz v. Amgen</i> 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed | <i>Amgen v. Sandoz</i> 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement; Appeal 20-1037 Affirmed, Request for <i>en banc</i> rehearing denied; Supreme Court 20-1110 Certiorari denied | <i>Amgen v. Samsung Bioepis</i> 2:19-cv-11755 (D.N.J.) Ongoing | <i>Coalition for Affordable Drugs v. Amgen</i> IPR2015-01792 Institution denied | <i>Coherus v. Hoffman-La Roche</i> IPR2017-01916 Institution denied | <i>Coherus v. Hoffman-La Roche</i> IPR2017-02066 Institution denied |
|-----------|--|---|--|---|---|---|
| 7,915,225 | | X | X | | | |
| 8,063,182 | X | X | X | | | X |
| 8,119,605 | | X | X | | | |
| 8,163,522 | X | X | X | X | X | |
| 8,722,631 | | X | X | | | |